ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
February 03 2021 - 4:30PM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced that
management will participate in the following investor conferences
in February:
- Guggenheim Healthcare Talks 2021 Oncology Day
– Participating in a virtual fireside chat on February 11, 2021 at
1:00 p.m. ET/10:00 a.m. PT; and
- LifeSci Partners Precision Oncology Day –
Hosting virtual investor meetings on February 17, 2021.
A live webcast of the fireside chat will be available through
the investor section of the company’s website at
www.oricpharma.com. A replay of the webcast will be available for
90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage
biopharmaceutical company dedicated to improving patients’ lives by
Overcoming Resistance In Cancer. ORIC’s lead product
candidate, ORIC-101, is a potent and selective small molecule
antagonist of the glucocorticoid receptor, which has been linked to
resistance to multiple classes of cancer therapeutics across a
variety of solid tumors. ORIC-101 is currently in two separate
Phase 1b trials in combination with (1) Xtandi (enzalutamide) in
metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in
advanced or metastatic solid tumors. ORIC’s other product
candidates include (1) ORIC-533, an orally bioavailable small
molecule inhibitor of CD73, a key node in the adenosine pathway
believed to play a central role in resistance to chemotherapy- and
immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric
inhibitor of the polycomb repressive complex 2 (PRC2) via the EED
subunit, being developed for prostate cancer, and (3) ORIC-114, a
brain penetrant inhibitor designed to selectively target EGFR and
HER2 with high potency against exon 20 insertion mutations, being
developed across multiple genetically defined cancers. Beyond these
four product candidates, ORIC is also developing multiple precision
medicines targeting other hallmark cancer resistance mechanisms.
ORIC has offices in South San Francisco and San Diego, California.
For more information, please go to www.oricpharma.com.
Investor Contact:Dominic Piscitelli, Chief
Financial
Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jul 2023 to Jul 2024